日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

VIKTORIA-1试验:Gedatolisib联合Fulvestrant,加或不加Palbociclib治疗激素受体阳性/HER2-/PIK3CA野生型晚期乳腺癌

Hurvitz, Sara A; Layman, Rachel M; Curigliano, Giuseppe; André, Fabrice; Cristofanilli, Massimo; Kim, Sung-Bae; Martínez Rodríguez, Jorge Luis; Nadal, Jorge C; Kim, Gun Min; Lo, Louisa; Remolina-Bonilla, Yuly A; Rosselli, Geronimo; Emile, George; Korbenfeld, Ernesto; Puig, Juan Manuel; Wesolowski, Robert; Martin, Miguel; Ring, Alistair; Han, Hyo S; Giordano, Antonio; Mutka, Sarah C; Moss, Keren; Suzuki, Sam; Sullivan, Brian; Gorbatchevsky, Igor; Pistilli, Barbara

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study

绝经前淋巴结阳性、激素受体阳性乳腺癌患者接受5年辅助促黄体生成素释放激素激动剂治疗后延长内分泌治疗:一项队列研究

Valenza, Carmine; Zheng, Yue; Milano, Monica; Trapani, Dario; Giordano, Elisa; Guidi, Lorenzo; Berton Giachetti, Pier Paolo Maria; Boldrini, Laura; Castellano, Grazia; Katrini, Jalissa; Malagutti, Bianca; Antonarelli, Gabriele; Conforti, Fabio; Pagan, Eleonora; Bagnardi, Vincenzo; Kirkner, Gregory J; Sangalli, Claudia; Dibble, Kate E; Colleoni, Marco; Regan, Meredith M; Munzone, Elisabetta; Curigliano, Giuseppe; Partridge, Ann H

Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer

出版商更正:APOBEC3 突变驱动乳腺癌治疗耐药性

Gupta, Avantika; Gazzo, Andrea; Selenica, Pier; Safonov, Anton; Pareja, Fresia; da Silva, Edaise M; Brown, David N; Shao, Hong; Zhu, Yingjie; Patel, Juber; Blanco-Heredia, Juan; Stefanovska, Bojana; Carpenter, Michael A; Chen, Yanjun; Vegas, Isabella; Pei, Xin; Frosina, Denise; Jungbluth, Achim A; Ladanyi, Marc; Curigliano, Giuseppe; Weigelt, Britta; Riaz, Nadeem; Powell, Simon N; Razavi, Pedram; Harris, Reuben S; Reis-Filho, Jorge S; Marra, Antonio; Chandarlapaty, Sarat

The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

液体活检和组织活检结果一致性对可操作突变的影响:来自 ROME 试验的启示

Botticelli, Andrea; Cremolini, Chiara; Scagnoli, Simone; Biffoni, Mauro; Lonardi, Sara; Fornaro, Lorenzo; Guarneri, Valentina; De Giorgi, Ugo; Ascierto, Paolo Antonio; Blandino, Giovanni; D'Amati, Giulia; Aglietta, Massimo; Conte, Pierfranco; Crimini, Edoardo; Ceracchi, Maurizio; Pisegna, Simona; Verkhovskaia, Sofia; Bordonaro, Roberto; Bracarda, Sergio; Butturini, Giovanni; Del Mastro, Lucia; DeCensi, Andrea; Fabbri, Agnese; Fenocchio, Elisabetta; Gori, Stefania; Metro, Giulio; Pessino, Annamaria; Pozzessere, Daniele; Puglisi, Fabio; Tamberi, Stefano; Zambelli, Alberto; Marino, Donatella; Capoluongo, Ettore; Cappuzzo, Federico; Cerbelli, Bruna; Giannini, Giuseppe; Malapelle, Umberto; Mazzuca, Federica; Nuti, Marianna; Pruneri, Giancarlo; Simmaco, Maurizio; Strigari, Lidia; Tonini, Giuseppe; Martini, Nello; Curigliano, Giuseppe; Marchetti, Paolo

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者的患者报告结局和定性访谈:来自III期EMBER-3试验的结果

Curigliano, G; O'Shaughnessy, J; Bidard, F-C; Casalnuovo, M L; Kim, S-B; Tokunaga, E; Aftimos, P; Saura, C; Carey, L A; Okera, M; Melo, E; Zagouri, F; Magallanes-Maciel, M; Karadurmus, N; Bahadur, S; Speck, R M; Wang, X A; Pradhan, K; Macey, J; Kitchen, H; Fairhurst, S; Miller, J; Jhaveri, K L; Harbeck, N

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer

新辅助帕博利珠单抗联合化疗治疗非转移性三阴性炎性乳腺癌,达到病理完全缓解

Lynce, F; Valenza, C; Niman, S M; Bertucci, F; Kai, M; Ryan, S; Troll, E; Layman, R M; Fanucci, K A; Giordano, A; Nasrazadani, A; Nakhlis, F; Bellon, J; Warren, L; Block, C; Schumer, S; Lucci, A; Krishnamurthy, S; Trapani, D; Lerebours, F; Dalenc, F; Levy, C; Petit, T; Leheurteur, M; Bachelot, T; Tredan, O; Ribeiro, J M; Pistilli, B; Zagami, P; Ladoire, S; Lopez Almeida, L; Zemmour, C; Carey, L A; Tolaney, S M; Valero, V; Curigliano, G; Regan, M M; Goncalves, A; Woodward, W A

Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer

乳腺癌中PI3K/AKT/mTOR通路抑制剂常见毒性的临床管理

Jhaveri, K L; Iyengar, N M; Turner, N C; Rugo, H S; O'Shaughnessy, J; Barrios, C H; Curigliano, G; André, F; Im, S-A; Goncalves, M D; Lacouture, M E; Fasching, P A; Leung, R

Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study

绝经前早期乳腺癌患者接受辅助性促性腺激素释放激素激动剂和芳香化酶抑制剂治疗时,卵巢功能抑制不足及内分泌治疗干预:一项队列研究

Valenza, C; Etessami, J D; Milano, M; Papadopoulos, N; Alvino, M; Antonarelli, G; Bianco, N; Sangalli, C; Trapani, D; Pravettoni, G; Omodeo Salè, E; Passerini, R; Colleoni, M; Munzone, E; Curigliano, G

Genomic landscape, immune microenvironment and survival in male versus female breast cancer

基因组图谱、免疫微环境与男性和女性乳腺癌患者的生存率

Trapani, D; Deshmukh, S K; Samec, T; Wu, S; Xiu, J; Walker, P; Abravanel, D L; Advani, P; Spanheimer, P M; Lin, N U; Curigliano, G; Graff, S L; Lustberg, M; Sledge, G W; Tolaney, S M; Leone, J P

A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer

一种用于预测激素受体阳性乳腺癌疾病复发的机器学习检测方法

Boscolo Bielo, L; Trapani, D; Razavi, P; Chandarlapaty, S; Zhan, Y; Curigliano, G